Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00295503 · FLOW

Participant flow

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma · Source last updated 2020-10-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    cisplatin 75 mg/m2, pemetrexed 500 mg/m2 and bevacizumab 15 mg/kg IV every 3 weeks
    id
    FG000
    title
    Cisplatin, Pemetrexed and Bevacizumab
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        53
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        53
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Patients recruited from investigators clinics
Complete source fields
groups
  1. description
    cisplatin 75 mg/m2, pemetrexed 500 mg/m2 and bevacizumab 15 mg/kg IV every 3 weeks
    id
    FG000
    title
    Cisplatin, Pemetrexed and Bevacizumab
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        53
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        53
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Patients recruited from investigators clinics

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice